These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 11699614)
1. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Hägg S; Spigset O; Lakso HA; Dahlqvist R Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614 [TBL] [Abstract][Full Text] [Related]
2. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212 [TBL] [Abstract][Full Text] [Related]
3. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842 [TBL] [Abstract][Full Text] [Related]
4. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. Okubo M; Narita M; Murayama N; Akimoto Y; Goto A; Yamazaki H Hum Psychopharmacol; 2016 Mar; 31(2):83-92. PubMed ID: 26856397 [TBL] [Abstract][Full Text] [Related]
5. The major fluvoxamine metabolite in urine is formed by CYP2D6. Spigset O; Axelsson S; Norström A; Hägg S; Dahlqvist R Eur J Clin Pharmacol; 2001 Nov; 57(9):653-8. PubMed ID: 11791895 [TBL] [Abstract][Full Text] [Related]
11. CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients. Fekete F; Menus Á; Tóth K; Kiss ÁF; Minus A; Sirok D; Belič A; Póti Á; Csukly G; Monostory K Sci Rep; 2023 Oct; 13(1):18507. PubMed ID: 37898643 [TBL] [Abstract][Full Text] [Related]
13. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Fliegert F; Kurth B; Göhler K Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019 [TBL] [Abstract][Full Text] [Related]
14. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755 [TBL] [Abstract][Full Text] [Related]
15. Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo. Larsen JT; Hansen LL; Brosen K Br J Clin Pharmacol; 1999 Nov; 48(5):663-8. PubMed ID: 10594467 [TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Lucas RA; Gilfillan DJ; Bergstrom RF Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152 [TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Spigset O; Hägg S; Söderström E; Dahlqvist R Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755 [TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Doki K; Homma M; Kuga K; Aonuma K; Kohda Y Br J Clin Pharmacol; 2009 Jul; 68(1):89-96. PubMed ID: 19660006 [TBL] [Abstract][Full Text] [Related]
19. Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations. Elmokadem A; Bruno CD; Housand C; Jordie EB; Chow CR; Lesko LJ; Greenblatt DJ J Clin Pharmacol; 2022 Jan; 62(1):66-75. PubMed ID: 34328221 [TBL] [Abstract][Full Text] [Related]